The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo

Idelalisib is a highly selective oral inhibitor of PI3Kδ indicated for the treatment of patients with relapsed chronic lymphocytic leukemia in combination with rituximab. Despite additive clinical effects, previous studies have paradoxically demonstrated that targeted therapies potentially negativel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunol
Main Authors: Palazzo, Adam, Herter, Sylvia, Grosmaire, Laura, Jones, Randy, Frey, Christian R., Limani, Florian, Bacac, Marina, Umana, Pablo, Oldham, Robert J., Marshall, Michael J. E., Cox, Kerry L., Turaj, Anna H., Cragg, Mark S., Klein, Christian, Carter, Matthew J., Tannheimer, Stacey
Formato: Artigo
Idioma:Inglês
Publicado em: AAI 2018
Assuntos:
Clinical and Human Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5857647/
https://ncbi.nlm.nih.gov/pubmed/29453281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1700323
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados